Literature DB >> 18544910

Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.

Katsumi Fukino1, Yuka Sasaki, Shigekazu Hirai, Takayuki Nakamura, Masayo Hashimoto, Fumio Yamagishi, Koichi Ueno.   

Abstract

For the purpose of a side-effect monitoring of isoniazid (INH), we investigated the relationship between the genotypes of drug-metabolizing enzymes involved in INH metabolism and the serum concentrations of INH and its metabolites in 129 tuberculosis patients hospitalizing in the National Hospital Organization Chiba-East Hospital. Genotype distributions of N-acetyltransferase 2 (NAT2), CYP2E1*5B, CYP2E1*6, Glutathione-S-transferase (GST) M1 and GST T1 were similar to those already reported in Japanese populations. Acetylating pathway of INH to acetyl isoniazid (AcINH) tended to shift to the hydrolytic pathway generating hydrazine (Hz) with the increase of mutant alleles in NAT2 gene. Serum concentration of Hz was significantly higher in slow acetylators than in rapid acetylators of NAT2. And also, serum concentration of Hz was significantly higher in the group that showed a high concentration of rifampicin (RFP) than in which RFP was not detected. The effect of CYP2E1 gene polymorphisms on the serum concentration of Hz was rarely observed, while that of GST gene polymorphism was observed in intermediate acetylators of NAT2. Hz tended to accumulate in patients with GST M1 null genotype. Therefore, it is conceivable that the risk factors of Hz accumulation are as follows: NAT2 slow acetylator phenotype, high concentration of serum RFP, and GST M1 null genotype. In these cases, we think it's necessary to pay attention to the development of hepatic disorder caused by Hz.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544910     DOI: 10.2131/jts.33.187

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  12 in total

1.  Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Vijay Ivaturi; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  Br J Clin Pharmacol       Date:  2016-12-09       Impact factor: 4.335

2.  Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia.

Authors:  Kamel Rouissi; Slah Ouerhani; Bechr Hamrita; Karim Bougatef; Raja Marrakchi; Mohamed Cherif; Mohamed Riadh Ben Slama; Mohamed Bouzouita; Mohamed Chebil; Amel Ben Ammar Elgaaied
Journal:  Pathol Oncol Res       Date:  2011-06-08       Impact factor: 3.201

3.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

4.  Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.

Authors:  Gustavo N O Costa; Luiz A V Magno; Cinthia V N Santana; Cibele Konstantinovas; Samuel T Saito; Moara Machado; Giuliano Di Pietro; Luciana Bastos-Rodrigues; Débora M Miranda; Luiz A De Marco; Marco A Romano-Silva; Fabrício Rios-Santos
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

5.  PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

Authors:  Ankit Balhara; Saranjit Singh
Journal:  Pharm Res       Date:  2021-09-13       Impact factor: 4.200

Review 6.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

7.  The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats.

Authors:  John Mach; Aniko Huizer-Pajkos; Sarah J Mitchell; Catriona McKenzie; Leo Phillips; Alice Kane; Brett Jones; Rafael de Cabo; Victoria Cogger; David G Le Couteur; Sarah N Hilmer
Journal:  Fundam Clin Pharmacol       Date:  2015-11-09       Impact factor: 2.748

8.  Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.

Authors:  Imir G Metushi; Tetsuya Nakagawa; Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2012-10-16       Impact factor: 3.739

9.  Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.

Authors:  Peter E Haroldsen; Marvin R Garovoy; Donald G Musson; Huiyu Zhou; Laurie Tsuruda; Boyd Hanson; Charles A O'Neill
Journal:  Pharmacol Res Perspect       Date:  2014-12-09

10.  Hair Analysis for Determination of Isoniazid Concentrations and Acetylator Phenotype during Antituberculous Treatment.

Authors:  Michael Eisenhut; Detlef Thieme; Dagmar Schmid; Sybille Fieseler; Hans Sachs
Journal:  Tuberc Res Treat       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.